Search research articles
Contact Us
Filters
Showing results (81-90 of 99) with videos related to
Page
of 10
Sort By:
Bone Marrow Transplantation
|
February 21, 2024
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM
Hoi Ki Karen Tang, Chi Yeung Fung, Yu Yan Hwang, et al.
Journal of Hematology & Oncology
|
June 12, 2012
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD
Chor Sang Chim, Albert Kwok Wai Lie, Eric Yuk Tat Chan, et al.
Annals of Hematology
|
September 3, 2024
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Annals of Hematology
|
May 23, 2025
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Annals of Hematology
|
September 23, 2024
Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Clinical Hematology International
|
August 11, 2025
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
Clinical Hematology International
|
May 8, 2026
Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
Gastroenterology
|
November 8, 2006
Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers
Bing Zou, Chor Sang Chim, Hui Zeng, et al.
Archives of Internal Medicine
|
December 14, 2005
Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia
Chor-Sang Chim, Yok-Lam Kwong, Albert Kwok-Wei Lie, et al.
American Journal of Hematology
|
April 12, 2014
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study
Kihyun Kim, Jae Hoon Lee, Jin Seok Kim, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 99) with videos related to
Sort By:
Page
of 10
Bone Marrow Transplantation
|
February 21, 2024
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM
Hoi Ki Karen Tang, Chi Yeung Fung, Yu Yan Hwang, et al.
Journal of Hematology & Oncology
|
June 12, 2012
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD
Chor Sang Chim, Albert Kwok Wai Lie, Eric Yuk Tat Chan, et al.
Annals of Hematology
|
September 3, 2024
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Annals of Hematology
|
May 23, 2025
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Annals of Hematology
|
September 23, 2024
Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Clinical Hematology International
|
August 11, 2025
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
Clinical Hematology International
|
May 8, 2026
Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
Gastroenterology
|
November 8, 2006
Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers
Bing Zou, Chor Sang Chim, Hui Zeng, et al.
Archives of Internal Medicine
|
December 14, 2005
Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia
Chor-Sang Chim, Yok-Lam Kwong, Albert Kwok-Wei Lie, et al.
American Journal of Hematology
|
April 12, 2014
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study
Kihyun Kim, Jae Hoon Lee, Jin Seok Kim, et al.
Page
of 10